Phaseline

Targets › CYP51

CYP51 (Lanosterol 14-alpha demethylase): drug programs, companies and trials

2 programs from 1 company in 2 trials: 2 Phase 4; Infectious disease.

Sterol 14alpha-demethylase that plays a critical role in the cholesterol biosynthesis pathway, being cholesterol the major sterol component in mammalian membranes as well as a precursor for bile acid and steroid hormone synthesis. Cytochrome P450 monooxygenase that catalyzes the three-step oxidative removal of the 14alpha-methyl group (C-32) of sterols such as lanosterol (lanosta-8,24-dien-3beta-ol) and…. (UniProt, Q16850)

Open in Phaseline: the race on CYP51, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Urooj FatimaFluconazole
Cytochrome P450 51 inhibitor
CYP51Phase 4Tinea Corporis–
Urooj FatimaItraconazole
Cytochrome P450 51 inhibitor
CYP51Phase 4Tinea Corporis–

Conditions

Tinea Corporis (2)

Modalities

small molecule (2)

Companies

Urooj Fatima (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.